Checkpoint Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
James Oliviero
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 38.7% |
| CEO tenure | 8.6yrs |
| CEO ownership | 1.0% |
| Management average tenure | no data |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20
Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?
Feb 06
Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?
Jan 27Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Dec 23What We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
Nov 27Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$636k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$54m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$2m | US$594k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$72m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$2m | US$540k | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$2m | US$515k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$480k | -US$25m |
| Sep 30 2019 | n/a | n/a | -US$28m |
| Jun 30 2019 | n/a | n/a | -US$32m |
| Mar 31 2019 | n/a | n/a | -US$33m |
| Dec 31 2018 | US$2m | US$450k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$31m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$645k | US$430k | -US$23m |
Compensation vs Market: James's total compensation ($USD1.64M) is above average for companies of similar size in the US market ($USD663.90K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
CEO
James Oliviero (47 yo)
8.6yrs
Tenure
US$1,641,591
Compensation
Mr. James F. Oliviero, III, CFA has been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 and also has been its Director since October 15, 2018. Mr. Olivier...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.6yrs | US$1.64m | 0.96% $ 540.0k | |
| Chairman of the Board | 9.2yrs | US$110.00k | 0.084% $ 47.6k | |
| Non-Executive Director | 9.5yrs | US$100.00k | 0.14% $ 79.2k | |
| Chairman of Scientific Advisory Board | 9.2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.8yrs | US$110.00k | 0.098% $ 55.5k | |
| Independent Director | 5.6yrs | US$100.00k | 0.091% $ 51.3k | |
| Independent Director | 8.3yrs | US$100.00k | 0.098% $ 55.5k | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data |
5.6yrs
Average Tenure
62.5yo
Average Age
Experienced Board: CKPT's board of directors are considered experienced (5.6 years average tenure).